{
    "organizations": [],
    "uuid": "ea36e589bd199107119a079f76bafc5ebdcd6d5f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-merrimack-provides-business-update/brief-merrimack-provides-business-update-and-reports-2017-financial-results-idUSASC09RPQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 12, 2018 / 10:45 AM / in 10 minutes BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results Reuters Staff March 12 (Reuters) - Merrimack Pharmaceuticals Inc: * MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS * ‍EXPECTS THREE CLINICAL READOUTS IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES​ * ‍ANNOUNCED FORMATION OF A NEW SCIENTIFIC ADVISORY BOARD WITH EXPERTISE IN PRECISION ONCOLOGY​ * MERRIMACK PHARMACEUTICALS -‍ CLOSURE OF 2017 WITH $93.4 MILLION IN CASH, CASH EQUIVALENTS, EXTINGUISHMENT OF $60.8 MILLION OF CONVERTIBLE DEBT IN Q4​ * MERRIMACK PHARMACEUTICALS - CONTINUES TO BELIEVE THAT CASH & CASH EQUIVALENTS AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO H2 2019 * Q4 LOSS PER SHARE $0.89 Source text for Eikon: Further company coverage:",
    "published": "2018-03-12T12:42:00.000+02:00",
    "crawled": "2018-03-12T13:01:50.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "minute",
        "provides",
        "business",
        "update",
        "report",
        "financial",
        "result",
        "reuters",
        "staff",
        "march",
        "reuters",
        "merrimack",
        "pharmaceutical",
        "inc",
        "merrimack",
        "provides",
        "business",
        "update",
        "report",
        "financial",
        "result",
        "three",
        "clinical",
        "readout",
        "including",
        "data",
        "two",
        "randomized",
        "phase",
        "formation",
        "new",
        "scientific",
        "advisory",
        "board",
        "expertise",
        "precision",
        "merrimack",
        "pharmaceutical",
        "closure",
        "million",
        "cash",
        "cash",
        "equivalent",
        "extinguishment",
        "million",
        "convertible",
        "debt",
        "merrimack",
        "pharmaceutical",
        "continues",
        "believe",
        "cash",
        "cash",
        "equivalent",
        "dec",
        "sufficient",
        "fund",
        "planned",
        "operation",
        "h2",
        "q4",
        "loss",
        "per",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}